Felix Dondorf

Dr. Felix Dondorf


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2017 in Der Chirurg
Verified
Journal Article
Closed access
PDF file
MAM. Ardelt
M. Ardelt
UDU. Dennler
U. Dennler
RFR. Fahrner
R. Fahrner
GHG. Hallof
G. Hallof
HTHans-Michael Tautenhahn
Hans-Michael Tautenhahn
USUtz Settmacher
Utz Settmacher

28 May 2019 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
FDFelix Dondorf
Felix Dondorf
FUFrank Uteß
Frank Uteß
RFRené Fahrner
René Fahrner
PFPhilipp Felgendreff
Philipp Felgendreff
MAMichael Ardelt
Michael Ardelt
FRFalk Rauchfuß
Falk Rauchfuß
Perihilar cholangiocarcinoma (Klatskin tumor) is a rare tumor entity, which is diagnosed late due to uncharacteristic symptoms. The therapeutic strategy for cure is still liver resection. Liver transplant in cases of locally irresectable tumors represents an alternative potential curative therapy for a select group of patients. We present our data of 22 patients with irresectable Klatskin tumors who received transplants between 1996 and 2015. We analyzed relevant prognostic factors for the selection of patients to be transplanted to ensure an acceptable overall survival and reviewed known and established selection criteria. Four factors (age, tumor size, serum level of carbohydrate antigen 19-9, percutaneous transhepatic cholangiodrainage) could be detected for possible patient selection. Positive lymph node status and advanced tumor stage according to the Union for International Cancer Control were confirmed as negative prognostic factors for survival after transplant. Liver transplant is a curative therapy for selected patients with irresectable Klatskin tumors, but further prospective studies are urgently needed.

13 March 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
FRFalk Rauchfuss
Falk Rauchfuss
ADAladdin Ali Deeb
Aladdin Ali Deeb
OROliver Rohland
Oliver Rohland
FDFelix Dondorf
Felix Dondorf
MAMichael Ardelt
Michael Ardelt
USUtz Settmacher
Utz Settmacher
Intrahepatic cholangiocarcinoma is in most transplant regions a contraindication for liver transplantation, even ruling out an active waiting list registration. However, recent studies showed that well-selected patients after a neo-adjuvant treatment benefit from liver transplantation with good long-term outcomes. The role of living donor liver transplantation is unclear for this indication. The current study focuses on LDLT for intrahepatic cholangiocarcinoma.

1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FDFelix Dondorf
Felix Dondorf
RFRené Fahrner
René Fahrner
MAMichael Ardelt
Michael Ardelt
EPEleonora Patsenker
Eleonora Patsenker
FSFelix Stickel
Felix Stickel
FRFalk Rauchfuss
Falk Rauchfuss
Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model

31 January 2022 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
FDFelix Dondorf
Felix Dondorf
MGMaximilian Graf
Maximilian Graf
ADAladdin Ali Deeb
Aladdin Ali Deeb
OROliver Rohland
Oliver Rohland
PFPhilipp Felgendreff
Philipp Felgendreff
FRFalk Rauchfuss
Falk Rauchfuss

13 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LSLaura Schwenk
Laura Schwenk
OROliver Rohland
Oliver Rohland
ADAladdin Ali Deeb
Aladdin Ali Deeb
FDFelix Dondorf
Felix Dondorf
USUtz Settmacher
Utz Settmacher
FRFalk Rauchfuss
Falk Rauchfuss
Background: Data about liver transplantation for mixed tumors from hepatocellular carcinoma to cholangiocarcinoma are limited. Furthermore, the diagnosis of intrahepatic cholangiocarcinoma or combined tumors in a cirrhotic liver is considered a contraindication for transplantation. Our aim was to evaluate the long-term outcomes of patients with incidental cholangiocarcinoma or combined tumors after liver transplantation. Methods: In our descriptive analysis, data were evaluated from all patients since 2010 who received a liver transplant due to an assumed hepatocellular carcinoma at Jena University Hospital. Survival rates were determined using the Kaplan–Meier method. Results: Between January 2010 and December 2022, an incidental intrahepatic cholangiocarcinoma was found in eight patients post-transplant. Four combined hepatocellular and cholangiocarcinoma and four sole intrahepatic cholangiocarcinomas were found. A recurrence through distant metastases from combined hepatocellular- and cholangiocarcinoma was found in one patient at one year after transplantation. Another patient developed a pulmonary primary tumor independently one year post-transplant. The recurrence rate was at 14.3%. While two patients died, the 1- and 5-year overall survival rates post-transplant were 87.5% and 75%, respectively. Conclusion: Patients with intrahepatic cholangiocarcinoma or combined hepatocellular- and cholangiocarcinoma could profit from liver transplantation.